

## REMARKS

Applicants submit the attached revised sequence listing in paper (C.F.R. 1.821(c)) and computer-readable form (C.F.R. 1.821(e)), along with applicants' statement under C.F.R. 1.821-1.825.


Minor non-substantive corrections to the Sequence Listing, as originally filed, have been made to bring the Sequence Listing into conformity with the requirements of C.F.R. 1.821-1.825:

The anti-sense oligonucleotide sequences of SEQ ID NOs:1-8 have each been reversed in direction only, because they were inadvertently listed in the 3' to 5' direction, rather than the required 5' to 3' direction. Support for this amendment is found throughout the originally filed specification and sequence listing where these oligonucleotides are disclosed as anti-sense oligos to the known HCMV US 28 receptor sequence. No new matter has been added.

The anti-sense oligonucleotide sequence of SEQ ID NO:21, which is complementary to the US28 receptor sequence region (beginning at nucleotide 165 of SEQ ID NO:1 and extending through nucleotide 185 thereof) has been revised to correct inadvertent mistakes in listing of the sequence at this region, so that the anti-sense oligo conforms with the known US28 receptor coding sequence at this position. Support for this amendment is inherently found in the sequence from nucleotide 165 through 185 of the originally filed SEQ ID NO:1, along with the explicit disclosure of SEQ ID NO:21 as an anti-sense oligonucleotide thereof. No new matter has been added.

Entry of this Preliminary Amendment is respectfully requested.

Respectfully submitted,



Barry L. Davison  
Attorney for Applicants  
Registration No. 47,309

Davis Wright Tremaine LLP  
2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Tel 206-628-7621  
Fax 206-628-7699